Sage Therapeutics(SAGE) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates Achieved $11 million in ZURZUVAE® (zuranolone) collaboration revenue during the third quarter of 2024 (50% of the net revenue recorded by Biogen), representing 49% growth from the second quarter Sage and Biogen will not pursue further development of zuranolone in major depressive disorder (MDD) in the U.S. Topline data from the DIMENSION Study in Huntington's Disease (HD) expected late ...